2019
DOI: 10.1016/j.jbspin.2018.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Bone disorders associated with diabetes mellitus and its treatments

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
53
0
2

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 59 publications
(55 citation statements)
references
References 64 publications
0
53
0
2
Order By: Relevance
“…Among numerous drugs used for HPI-related diseases many are well known to contribute to OP/OFs. In regard to OP, these include corticosteroids, antidepressants (especially, selective serotonin- and serotonin-norepinephrine reuptake inhibitors), glitazones, opioids, benzodiazepines, antipsychotics, antiparkinsonian drugs, antiepileptics, PPIs, H2RA, thyroxine, furosemide, aromatase inhibitors, gonadotropin releasing hormone (GnRH) agonists, whereas hormone replacement therapy with estrogen, thiazides, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), spironolactone, beta-blockers, statins, antihistamines, metformin, sulphonylureas, glucagon-like peptide-1 receptor agonists (liraglutide) and nitrates have shown an osteoprotective effect [ 316 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 ].…”
Section: Hpi-associated Chronic Extra-gastroduodenal Diseases Medmentioning
confidence: 99%
See 1 more Smart Citation
“…Among numerous drugs used for HPI-related diseases many are well known to contribute to OP/OFs. In regard to OP, these include corticosteroids, antidepressants (especially, selective serotonin- and serotonin-norepinephrine reuptake inhibitors), glitazones, opioids, benzodiazepines, antipsychotics, antiparkinsonian drugs, antiepileptics, PPIs, H2RA, thyroxine, furosemide, aromatase inhibitors, gonadotropin releasing hormone (GnRH) agonists, whereas hormone replacement therapy with estrogen, thiazides, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), spironolactone, beta-blockers, statins, antihistamines, metformin, sulphonylureas, glucagon-like peptide-1 receptor agonists (liraglutide) and nitrates have shown an osteoprotective effect [ 316 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 ].…”
Section: Hpi-associated Chronic Extra-gastroduodenal Diseases Medmentioning
confidence: 99%
“…Some agents have shown divergent effects on bone and skeletal muscles. For example, thiazolidinediones demonstrate detrimental effect on the skeleton and increase fracture risk [ 545 , 599 , 600 , 601 , 602 , 603 , 604 ] but a beneficial effect on muscle atrophy [ 605 ]; other anti-diabetic drugs (sulfonylureas, metformin and possible incretin mimetics) have a neutral or a positive/protective effect on bone health, but they may increase propensity for falls through hypoglycemia (insulin and sulfonylureas) [ 601 , 603 , 604 , 606 ]. When analyzing the complex relationships between OFs and drugs used it should also be taken into account that many medications (corticosteroids, sulfonamides, urea derivatives, vitamin K antagonists, cardiac glycosides, loop diuretics, potassium-sparing diuretics, ACE inhibitors, serotonin reuptake inhibitors, calcium-channel blockers and antiepileptic drugs) may affect the vitamin D status and calcium homeostasis [ 607 , 608 , 609 , 610 , 611 ].…”
Section: Hpi-associated Chronic Extra-gastroduodenal Diseases Medmentioning
confidence: 99%
“…Patients with type 2 diabetes mellitus (T2DM) are at increased risk for bone fracture independent of bone mineral density (BMD). 1,2 Recent studies focused on bone structure quality have shown that trabecular and cortical bone microstructure are more fragile in patients with T2DM. [3][4][5][6] These findings have led to increased interest in the mechanisms of T2DM-induced bone microstructure damage, with the goal of developing new treatments for T2DM-induced osteoporosis.…”
Section: Introductionmentioning
confidence: 99%
“…Many studies have found that patients with hepatic failure have an increased risk of osteoporosis; the pathogenesis of bone loss and osteoporosis in patients with hepatic failure is complex and multifactorial [7,9]. A study reported that low levels of insulin-like growth factor 1 in patients with advanced liver cirrhosis may aggravate bone remodelling and maintenance of bone mass in elderly patients, causing fragility fractures [10,11]. In addition, patients with HE have demonstrated poor cognitive function and are often a icted by psychiatric illnesses, which may increase the risk of sustaining an injury due to a fall [5].…”
Section: Discussionmentioning
confidence: 99%